GRI Bio, Inc. — fact timeline

GRI Bio, Inc. amended Amendment No. 1 to At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering fr (effective 2026-01-28).

“On January 29, 2026, the Company entered into an Amendment No. 1 to At The Market Offering Agreement (the “Amendment”) with Wainwright, effective as of January 28, 2026, to increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering from $10,000,000 to up to the dollar amount of Shares registered on the prospectus supplement pursuant to which the ATM Offering is being made.”

GRI Bio, Inc.: Filed Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock, effective January 23, 2026 (effective 2026-01-23).

“On January 21, 2026, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-28 (the “Reverse Stock Split”).”

GRI Bio, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 15, 2026, GRI Bio, Inc. (the “Company”) was formally notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined that the Company has conditionally regained compliance with the equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) which requires that companies listed on the Nasdaq Capital Market with a market value of less than $35 million and annual net income of less than $500,000 maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”). As previously reported on the”

GRI Bio, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 26, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and a”

GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.

“GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update”

GRI Bio, Inc. reported financial results for fiscal year ended December 31, 2023.

“On April 1, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2023, and provided a business update.”